Conference Call and Webcast Scheduled for 8:30 AM ET RA’ANANA, Israel and NEW YORK , March 08, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN) today announced that it will report fourth quarter and full year 2017 financial results on Thursday, March 15, 2018 , prior to the open of the
RA’ANANA, Israel and NEW YORK , March 07, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN) today announced that management plans to present at two investor conferences in March 2018 : Cowen & Company 38 th Annual Health Care Conference Tuesday, March 13 8:00AM Eastern Time Boston, MA
RA’ANANA, Israel and NEW YORK , Feb. 14, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the appointment of Stephen Mullennix as
RA’ANANA, Israel and NEW YORK , Jan. 23, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the closing of its public offering of
RA'ANANA, Israel and NEW YORK , Jan. 18, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the pricing of its public offering of
RA’ANANA, Israel and NEW YORK , Jan. 16, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that it filed a registration statement
Kate Bechtold , Also Formerly of Kite Pharma, to Join the Expanded Communications Team as Director of Corporate Communications & Investor Relations RA’ANANA, Israel , and NEW YORK , Jan. 08, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company
RA’ANANA, Israel and NEW YORK , Jan. 02, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Ron Bentsur , the Company’s Chief
Mark Schoenberg , M.D., Named Chief Medical Officer Elyse Seltzer , M.D., Appointed Senior Vice President of Clinical Development RA'ANANA, Israel and NEW YORK , Dec. 12, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to
Principal Investigator Seth Lerner , M.D., to present design overview of ongoing Phase 3 OLYMPUS trial of MitoGel™ for the treatment of Low-Grade UTUC and data highlights from recently completed compassionate use program RA’ANANA, Israel and NEW YORK , Nov.
